Cencora reported fiscal 2026 first‐quarter revenue of $85.9 billion, a 5.5 percent increase year-over-year, driven by a 5.0 percent gain in U.S. Healthcare Solutions and a 9.6 percent rise in International Healthcare Solutions. Adjusted diluted EPS of $4.08 exceeded the Zacks Consensus Estimate of $4.07 and rose 9.4 percent from $3.73 in the prior‐year quarter. On a GAAP basis, diluted EPS was $2.87 versus $2.50 a year ago, representing a 14.8 percent improvement.

Gross profit under GAAP climbed 20.1 percent to $3.1 billion, lifting the gross margin by 44 basis points to 3.58 percent, driven by higher specialty‐product margins and a favorable LIFO credit. Adjusted gross profit increased 18.1 percent to $3.0 billion, with a 37 basis‐point margin expansion to 3.48 percent. GAAP operating income grew 7.7 percent to $760 million (0.88 percent of revenue), while adjusted operating income rose 11.9 percent to $1.1 billion (1.24 percent of revenue).

Net interest expense was $72.4 million, up by $44.5 million year-over-year, reflecting financing costs associated with senior notes and a term loan for the January 2025 acquisition of Retina Consultants of America. The GAAP effective tax rate was 20.1 percent, slightly below last year’s 20.4 percent, while the adjusted effective tax rate declined from 20.0 percent to 19.0 percent.

Cencora raised its adjusted operating income growth outlook for fiscal 2026 to a range of 11.5 percent–13.5 percent, up from the prior 8 percent–10 percent forecast, reflecting the integration of OneOncology and strong performance in its U.S. Healthcare Solutions segment. CEO Robert P. Mauch highlighted that the OneOncology acquisition cements Cencora’s specialty medical‐service‐organization footprint and enhances its partnerships with leading cancer‐care physicians.